Clinical Trials Logo

Advanced Biliary Tract Cancer clinical trials

View clinical trials related to Advanced Biliary Tract Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05823987 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)

OPTIONS-05
Start date: May 16, 2023
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of oncolytic virotherapy combined with Tislelizumab plus lenvatinib in patients with advanced biliary tract cancer (BTC).

NCT ID: NCT05820906 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Cadonilimab in combination with Regorafenib and Gem-Cis chemotherapy in advanced biliary tract Cancer

NCT ID: NCT05812430 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer

Start date: April 10, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of anlotinib plus TQB2450 combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer

NCT ID: NCT05781074 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer (CASTLE-08)

CASTLE-08
Start date: March 23, 2023
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus lenvatinib in patients with Immune Checkpoint Inhibitor previously treated advanced biliary tract cancer (BTC).

NCT ID: NCT05653180 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Start date: March 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is designed to establish whether the combination of IBI310 & Sintilimab has efficacy in patients with advanced BTC

NCT ID: NCT05410197 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)

Start date: October 10, 2022
Phase: Phase 2
Study type: Interventional

This is a phase 2, single-arm, open label study. The purpose is to investigate both the efficacy and safety of Envofolimab and Lenvatinib in combination with Gemcitabine plus Cisplatin for treatment of advanced biliary tract cancer as first-line treatment.

NCT ID: NCT05170438 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment

LenPac
Start date: July 1, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the following items in patients with advanced cholangiocarcinoma receiving lenvatinib plus paclitaxel treatment, Primary endpoint: Overall response rate (ORR) by RECIST 1.1 Secondary endpoints Progression-free survival (PFS) Time to progression Overall survival Disease control rate (Overall response rate + stable disease ≧ 4 weeks) Response rate by modified RECIST Association between therapeutic efficacy and tumor vascularity Quality of life Safety profile Predictive biomarker of cholangiocarcinoma

NCT ID: NCT04781192 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

Start date: March 22, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to measure how effective combining Durvalumab and Regorafenib will be for participants with advance stage biliary track carcinoma who have received one line of prior treatment

NCT ID: NCT04211168 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Start date: August 11, 2020
Phase: Phase 2
Study type: Interventional

The investigators design a phase II clinical study to explore the efficacy and safety of toripalimab plus lenvatinib as a second-line treatment in patients with advanced biliary tract cancers and to analyze potential biomarkers of therapeutic response.

NCT ID: NCT04027764 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer

Start date: May 1, 2019
Phase: Phase 2
Study type: Interventional

The investigator's study is a single armed phrase II trial ,aiming to improve the effecacy of treatment for advanced billiary tract cancer by means of Toripalimab combining with S1 and Albumin Paclitaxel as first line in patients with advanced Biliary Tract Cancer. treatment continually until disease progression or intolerable toxicity or Patients withdrawal of consent.and target sample is 30+ patients.